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ABSTRACT
DANAZOL AS A STEROID ENZYME INHIBITOR
IN RAT ADRENAL GLANDS
Frank A. Miklavcic
Morehead State Univ
Director of Thesis:
The effect of Danazol, a synthe ic steroid derivative, as an inhibitor of the enzymes of st·eroidogenesis,
was studied in the adrenal glands of adult female rats
in vivo.

Analysis was made of adrenal weight, zona

glomerulosa histology, and electrolyte concentration in
the urine and blood plasma.
Changes in sodium, potassium, and chloride ion
concentrations in the urine and plasma of Danazol injected rats with ovaries intact suggest the possible inhibition of the synthesis of aldo?terone.

However, castrated

rats injected with Danazol exhibited no differences in
the characteristics analyzed when compared to the castrate
control group.

This suggests that Danazol may affect the

adrenal glands by way of its influence on estrogen
release from the ovary.

Another explanation may be that

estrogens have a permissive action on the means by which
Danazol affects the adrenals.
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INTRODUCTION
Danazol, a 2,3-isoxazol derivative of ethinyl
testosterone, was developed by Manson, et al. ll-963) at
Sterling-Winthrop Research Institute.

The chemical name

for Danazol (brand name Danocrine) is 17a-pregn-2,4dien-20-yno-[2,3-d]-isoxazol-17-ol.

It has the basic

structure of testosterone along with an ethinyl group
at C-17 and an isoxazol ring replacing the keto group
at C-3 (Figure 1.).
According to Dmowski, et al. (1979) Danazol is
currently approved by the Food and Drug Administration
for use in the treatment of endometriosis.

Clinically

it has also been used for the treatment of chronic
cystic mastitis, gynecomastia, precocious puberty,
congenital angioneurotic edema, and as a male and female
contraceptive.

Danazol, if taken orally, is absorbed

through the gastro-intestinal tract and metabolized
quickly in the body, having a half-life of 4.5 hours in
humans and reaching a peak in human female plasma two
hours after administration.

In monkeys and rats, however,

plasma peak was reached four to eight hours after
administration.
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Chemical Structure of Danazol
Figure 1.
Danazol is metabolized in the liver by the cleavage
of the isoxazol ring with over sixty of its metabolites
having been isolated, the major one being 2-hydroxymethylethisterone.

According to Rosi, et al. (1977),

Danazol, rather than one of its metabolites, appears to
cause the biologic effects.

None of the metabolites

exhibited the antigonadotropic or androgenic activities
of Danazol, and when Danazol was administered with its
metabolic blockers, its biological activities greatly
increased.

In studies with radioactive Danazol, high

concentrations of radioactivity were noted in the liver,
kidneys, and adrenals when compared to the concentration
in the blood plasma.
When Danazol was first marketed, advertising and
pharmacological bulletins indicated that the primary
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effect was suppression of the pituitary-ovarian axis by
inhibiting the secretions of the gonadotropins FHS and LH
from the pituitary.

According to Dmowski, et al. (1977),

Danazol appeared to have no progestational or estrogenic
effect and only mildly androgenic side effects, which
appeared in the form of acne, edema, mild hirsutism, and a
decrease in breast size.

Barbieri, et al. (1979) have

stated that studies actually indicated that Danazol has at
least four pharmacological properties:

1) direct

inhibition of gonadotropin synthesis and/or release, 2)
direct inhibition of the multiple enzymes of steroidogenesis, 3) interaction with androgen, glucocorticoid, and
progesterone receptors in target tissues, and 4)
alteration bf endogenous steroid metabolism.
The antigonadotropic effect of Danazol was
reported by Greenblatt and Dmowski (1971) because it had
no effect when administered with exogenous gonadotropins.
Greenblatt, -et al. (1974) indicated the possible use of
Danazol as a contraceptive agent because of the drop in
FSH and LH levels at a dosage of 100 mg per day and, in
particular, the prevention of the mid-cycle LH surge
prior to ovulation.

Van Dijk, et al. (1979) have used

Danazol for treating unexplained infertility in women.
Women with infertility diagnosed as unexplainable by all
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known clinical tests were administered Danazol orally with
a control group receiving placebos.
and

Anovulation occurred,

upon cessation of treatment, a significant number of

the treated group conceived within six months while none
of the placebo group did.

No explanation as to why

conception occured was discernible.

Franchimont and

Cramilion (1977) reported that FSH and LH were the only
hormones of the anterior pituitary inhibited, as no
changes in the response of ACTH, TSH, or prolactin were
noted.
Mild androgenic effects have been observed
clinically, especially at higher doses, but more anabolic
rather than androgenic effects seem to appear at these
higher doses.

Barbieri, et ~-

(1979) have done

extensive work on the receptor binding ability of Danazol
and have noted that Danazol displaces 311-dihydrotestosterone from the 8S androgen receptor of the prostate
cytosol along with positive results of the androgen
bioassay using ventral prostate and seminal vesicle
weights.

This receptor binding correlates with the mild

androgenic side effects.

Potts, et al.

(1974) have

referred to Danazol as an impeded androgen since a high
dose of 672 mg/kg/day produced effects comparable to a
low dosage of only 84 mg/kg/day.
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Danazol exhibits no estrogenic effects.

Barbieri,

et al. (1979) reported slight gains in uterine weights in
immature female rats, but when compared to the effect
produced by the estrogen compound mestranol, Danazol
produced less of a uterine weight gain at ten thousand
times the concentration of mestranol.

They also noted

that no vaginal cornification occurred at a dosage of
40 mg/kg/day.

In correlation Danazol bound only very
weakly to the rat uterine cytosol in displacing 3H-estradiol.

Potts, et al. (1974) compared the slight uterine

weight gain to that caused by androgens.
Whether Danazol is a progestational or anti-progestational agent still remains controversial.

While Potts,

et al. (.1974) showed that Danazol has no progestational
effect in the Clauberg assay, Dmowski, et al. (1971) and
Wentz and Sapp (1978) have reported endometrial secretory
changes with Danazol treatment, although the changes were
atypical of those induced by progesterone.

Creange,

et al. (1974) developed a radioligand assay for Danazol
using a protein which has a high specificity for
progesterone.

In determining the effect of Danazol as a

luteolytic contraceptive, however, Wentz and Sapp (1978)
reported a rise in progesterone levels following HCG
injections after Danazol treatment, indicating that
Danazol does not have the luteolytic effect of
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progesterone.

The~e facts plus the reported evidence by

Barbieri, et al. (1979) that Danazol binds to the rat
uterine cytosol receptor leave the progestationalantiprogestational controversy still be researched
further.
Barbieri, et al.

(1979) have demonstrated the

glucocorticoid effect of Danazol by the liver glycogen
assay and by the ability of Danazol to bind to the
glucocorticoid receptor of the rat liver cytosol.
Franchimont and Cramilion (1977) showed that serum
cortisol levels were significantly lower in Danazol
treated patients; however, Wentz, et al.

(1975) have

reported that Danazol has no apparent effect on the
adrenal gland's ability to respond to ACT!!.

Their methods

included the injection of the synthetic ACTH compound
cosyntropin in Danazol treated patients as well as the
injection of the 118-hydroxylase inhibitor metyrapone.
The cosyntropin challenge produced an increase in plasma
cortisol levels, and the metyrapone challenge caused a rise
in 17-hydroxysteroid

levels.

Barbieri, et al. (1977) have reported the inhibition
of steroidogenesis in hamster ovaries, rat testes, and
rat adrenals in vitro.

In rat adrenals the 38-hydroxy-

steroid dehy,drogenase and 21-hydroxylase enzymes of the
cytoplasm and the 118-hydroxylase enzyme of the mite-
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chondria are inhibited by Danazol.

He mentioned that a

number of previous reports of antigonadotropic effects by
Dmowski, et al. (1971) and Potts, et al. (1974) in
hemicastrates and castrates could actually have been
caused by the inhibition of steroidogenesis.

Sherins,

et al. (1971) also noted changes in gonadal steroid levels
in humans with no corresponding FSH or LH changes.
There are four main groups of adrenal cortical
steroids (Greenberg, 1968): 1) the 11-oxygenated
corticosteroids or glucocorticoids which affect carbohydrate metabolism and include primarily cortisol,
corticosterone, 11-dehydrocorticosterone and cortisone,
2) the corticoids lacking oxygen at C-11 or mineralocorticoids which include 11-deoxycorticosterone (DOC),
and 11-deoxycortisol, 3) aldosterone which is the most
potent steroid involved in electrolyte metabolism and has
an aldehyde group at C-18, and 4) the sex steroids.
Since the adrenal cortex, testes, ovaries, and
placenta are all centers of steroid synthesis,

it has

been shown that they all contain the same enzyme systems.
The C-27 molecule cholesterol is the precursor of almost
fifty different steroids produced by the adrenal cortex.
The first step is the conversion of cholesterol to the
C-21 molecule pregnenolone by a cytochrome P-450 enzyme of
the mitochondria which requires NADPH and molecular oxygen
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and cleaves the side chain from cholesterol.

The side

chain cleavage step appears to be the rate limiting step
in steroid biosynthesis (Figure 2, Boyd, et al.

(1978).

Pregnenolone can be converted to either progesterone
or 17a-pregnenolone.

The pathways from 17a-pregnenolone

lead to synthesis of the androgens and estrogens, but only
the pathways leading to the mineralocorticoids and the
glucocorticoids will be discussed here.
Pregnenolone is converted to progesterone by
38-hydroxysteroid dehydrogenase requiring NAD+ as a
hydrogen acceptor and ~ 5 -3-oxoisomerase which shifts the
double bond from the numbers 5 and 6 carbons to the
numbers 4 and 5 carbons.

Progesterone can then be

converted to 17a-hydroxyprogesterone by a 17a-hydroxylase
associated with the cytoplasm.

This pathway is prevalent

in humans but does not exist in rats.

A microsomal

21-hydroxylase then converts 17a-hydroxyprogesterone to
11-deoxycortisol, a mineralocorticoid which is then
converted by the mitochondrial cytochrome P-450 118hydroxylase system to cortisol, the primary glucocorticoid
in humans.
Another pathway from progesterone, the primary one
in rats, has a 21-hydroxylase product, 11-deoxycorticosterone (DOC), a mineralocorticoid comparable to 11-deoxycortisol.

DOC is then converted by the 118-hydroxylase to
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corticosterone, the primary glucocorticoid in rats.
Corticosterone can then be converted to the very potent
mineralocorticoid aldosterone by 18-hydroxylase and
18-hydroxy dehydrogenase found in the mitochondria.

Once

synthesized, aldosterone can be found either in the
18-aldehyde form or in the more common 11-18 hemiacetal
form.
Sabatini and DeRoberts (1961) reported that, while
3S-hydroxysteroid dehydrogenase, llS-hydroxylase, and
21-hydroxylase activity occur throughout the cortex, the
18-oxygenation to aldosterone is located only in the
outer most zona glomerulosa, and the 17-hydroxylase
activity is localized in the inner zona fasciculata or
the zona reticularis.

They originally reported the

transformation of the zona glomerulosa into fasciculata
cells upon chronic administration of ACTH, but more
recently it has been shown that the zona glomerulosa and
zona reticularis are independent of each other (Turner
and Bagnara, 1976).

Watanuki, et al. (1978) have provided

evidence that the llS-hydroxylase and 18-hydroxylase
activities, which are part of the cytochrome P-450 complex,
are actually catalyzed by only one enzyme.
It is the purpose of this research to further
explore the effects of Danazol on the rat adrenal cortex.
This will be done by studying the effects of Danazol
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on adrenal weight, electrolyte concentrations in the urine
and blood, and the histology of the zona_ glomerulosa.
Electrolyte levels to .be analyzed are sodium, potassium,
and chloride concentrations.

The first experiment will

analyze the dosage level effect on these characteristics
related to adrenal cortical steroidogenesis.

From this an

optimal dosage will be chosen to be used in a prolonged
study of adrenal cortical response to Danazol.
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MATERIALS AND METHODS
Animal Care
Two experiments were performed on adult female
Sprague-Dawley rats.

The rats were housed three per

cage at 23° C. under a regimen of ten hours darkness and
fourteen hours of artificial lighting.

They were allowed

access to water and Purina Rat Chow ad libitum.
Experiment I
Twelve rats were injected with Nembutal (4 mg/ 100 gm
body weight) and ovariectomized.

Four days following sur-

gery, the rats were divided into four groups and injected
in the hind leg with Danazol (Sterling-Winthrop Labs)
dissolved in peanut oil with Groups 2,3, and 4 receiving
2,4, and 8 mg/kg body weight/day respectively and Group 1
receiving a corresponding injection of peanut oil as a
control.

Four groups of rats with ovaries intact were

injected with doses corresponding to Groups 1,2,3, and 4.
Injections of all eight groups were continued for ten
days.

On the tenth day urine samples were taken by

applying pressure in the area of the kidneys.

Urine

samples were stored in disposable culture tubes and
frozen.

Twenty four hours following the final injection,

the rats were removed from the rat room in groups of
three, stunned and decapitated within two minutes of
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removal from the quarters to prevent the influence of
ACTH release into the bloodstream.

Blood was drained

from the necks into 400 ml beakers, transferred to 15 ml
disposable centrifuge tubes, centrifuged for 15 minutes
at 1550 rpm, and the plasma frozen.

The right adrenal

was removed and placed in fixative to prevent degradation of the zona glomerulosa.

The left adrenal was

weighed, as were the ovaries of the intact• rats.
The right adrenal was treated for removal of mercury
with a saturated iodine-alcohol solution, dehydrated in
alcohol and toluene, embedded in paraffin, sectioned at
ten microns, stained with Delafield's hematoxylin, and
counterstained with eosin by the method of Humason (1972).
The zona glomerulosa thickness was measured under l00X
with an optical micrometer.
Ten lambda samples of urine and one hundred lambda
samples of serum were measured for chloride ion concentration with a digital chloridometer (Buchler).

Twenty

lambda samples of urine and fifty lambda samples of serum
were analyzed for sodium and potassium ion levels by
flame photometry (Coleman Model 21).
Experiment Il_
Twelve adult female rats were ovariectomized as per
Experiment I.

Four days following surgery, six castrated
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females were injected with peanut oil as a control, while
six were injected with a dosage of 4 mg/kg/ Body weight of
Danazol dissolved in peanut oil.

Two groups of six rats

each with ovaries intact were. given corresponding injections.
Injections were continued for twenty days.

Post treatment

protocol was followed as in Experiment I.
Analysis of Data
All data was analyzed using the Student's t test.
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RESULTS
Experiment I
Danazol caused no significant change in body weight
in adult female rats, castrated or not, at the doses
administered during the ten day experiment (Table 1).
A significant increase in adrenal weight was
observed in the castrate control group compared to the
intact controls (Table 1).
This experiment showed the most measurable effects
of Danazol at a dosage of 4 mg/kg which corresponds to
the reported dosage used by Dmowski, et al. (1971).

At

this dosage adrenal weight decreased compared to the
control in castrates only, while intact rats showed a
significant decrease in ovarian weight (Table 1).

This

dosage also caused an elevation of the serum Na+ levels
and a decrease in Na+/K+ ratios (Table 2), as well as an
elevation of the urine Na + levels in intact rats compared
to the intact controls (Table 2).

Castrates at the 4 mg/kg

dosage exhibited a lowering of the serum K+ levels and
an increase in the Na+/K+ ratios compared to the intact
rats receiving this dosage (Table 2).
A dosage of 2 mg/kg produced an increase in the
Na+;K+ ratios in castrates compared to intact rats
receiving this injection (Table 2), while a dosage of

TABLE 1.
EXPERIMENT I
BODY WEIGHT CHANGE AND RELATIVE ADRENAL AND OVARIAN WEIGHTS
Dosage (mg/kg
body weight)

* Change in Body
Weight
(gm)

*Relative Ovarian
*Relative Adrenal
Weight (mg/ 100 gm Weight (mg/ 100 gm
body weight)
body weight)

10.7 ± 1. 3a

0

+10 ± 19

2

+10

±

21

4

-7

±

7

6.1 ± 1. 4b

8

+3

±

5

9.4 ± 2.3

0

-2

±

4

6.9 ± 0.8

6.4 + 0.9

2

+3

±

5

6.2

±

1.0

4.5 ± 1. 2

4

-4 ±

4

7.8

±

0.3

4.8 + 0.5c

8

+4

7

6.2 ± 1. 2

µ.i

E--<

8.0 + 1. 2

0,:

E--<
CJ)

u

E--<

u

E--<

z

*Mean±
(a P<.02
(b P£.02
(C P£.05

Standard
compared
compared
compared

±

Deviation
to Intact· Control)
to Castrate Control)
to Intact Control)

5.4

±

1.1

TABLE 2.
EXPERIMENT I
ION CONCENTRATIONS AND RATIOS IN THE BLOOD

c1-

K+

Na+
(meq/ 1)
*

(meq/1)

0

109 t 67

E---<
~

2

E---<
Ul
~

Dosage (mg/kg
body weight)

(meq/ 1)
*

*

13.0 t 4.6

81 t 17

7.1 t 3.4

152 t 33

12.0 t 2.6

67 t 16

4

150 t 13

15.3 t 2. 0

80 t

3

9.9 t 1.5

8

120 t 26

19.7 + 6. 9

78 t

8

6.4 t 1.5

0

118 t 30

16.3 t 2. 3

81

t

14

7.3 t 0. 8

u

2

102

t

16.7

t

4.4

84

t

15

6.4

t

2.0d

zH

4

83

t

21.0

t

o.ob,c

86

t

8

4.0

t

o.sa,b

8

90

t

21. 0

±

3.6

88

t

14

4.4

t

1. 2

µ:i

0::

u

*

12.7

t

E---<
~
E---<

28
3a
10

* Mean± Standard Deviation
ca P.::: . 01 compared to dosage
( b P.::: . 01 compared to intact
cc po<: .02 compared to dosage
Cd P .c:. 02 compared to dosage

of 4 mg/kg in castrates)
control)
of 4 mg/kg in castrates)
of 2 mg/kg in castrates)

1. 4

I-'

---,

TABLE 3.
EXPERIMENT I
ION CONCENTRATIONS AND RATIOS IN THE URINE

Dosage (mg/kg
body weight)

Na+

ci-

(meq/1)
*

(meq/1)

*

*

0

118 ± 71

74 ± 68

131 ± 127

1. 9 ± 0.8

2

179 ± 42

114 ± 46

186 ± 105

1. 7 +- 0.4

4

175 + 13

175 ± 53

194 ±

45

1.0 ± 0. 5

8

156 ± 43

155 ± 22

227 ±

69

1.0 + 0. 5

0

143 ± 19

174 ± 23

195 +-

18

0.8 ± 0.6

<r:

2

171 ± 28

140 ± 40

196 ±

60

1. 3 + 0.4

zH

4

216 ± 27 a

184 ± 18

288 ±

70

1. 2 +- 0.3

8

191 ± 19 a

169 ± 31

263 ±

~

E-<

<r:

pc:
E-<
(f)

<r:

u

E-<

u

E-<

*Mean± Standard Deviation
ca P ~. 02 compared to Intact Control)
(b P..:::: . 01 compared to Intact Control)

6b

1. 2 ± 0.1

f-00
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eight mg/kg significantly elevated urine Na+ and Cllevels in intact females only (Table 3).
Experiment II
Administration of Danazol over a twenty day period
again produced no significant change in body weight at
any of the doses administered (Table 4).
Injections of Danazol for twenty days caused a
decrease in adrenal weights in both treated groups, but
the castrate control group also exhibited a decrease in
weight which was not significantly different from that of
treated castrates (Table 4).

Intact rats injected with

Danazol exhibited a significantly lower ovarian weight
compared to the intact control rats (Table 4).
+

Danazol also caused an elevation of serum K levels
.

+

and a decrease in the Na /K

+

.

ratios in the serum of intact

rats (Table S), but the effect of castration alone was
to elevate the serum K+ levels (Table S) as well as the
levels of urine chloride ions (Table 6).
Zona glomerulosa thickness decreased in both groups
treated with Danazol compared to the intact control
group, but castration alone also caused the glomerulosa
layer to diminish in size (Table 7).
Finally it should be noted that in all the data
obtained (adrenal weight, ion concentrations and ratios,
and thickness of the zona glomerulosa) not one significant
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difference was observed between Danazol injected castrates
and control castrates.

TABLE 4.
EXPERIMENT II
BODY WEIGHT CHANGE AND RELATIVE ADRENAL AND OVARIAN WEIGHTS

Treatment

Intact Control

*Change in Body
Weight
(gm)

-1., 10

*Relative Adrenal
Weight (mg/ 100 gm
body weight)

9.7., 0.2

*Relative Ovarian
Weight (mg/ 100 gm
body weight)

11.4 ± 2.5

-------------------------------------------------------------------------------+8., 14

7.0 ± 1.3

Castrate Control

-5

7.1 t 0.4

Castrate Danazol

-2 ± 10

Intact Danazol

±

15

*Mean± Standard Deviation
(a P .C::. 001 compared to Intact Control)
(b p,.::.. 01 compared to Intact Control)

a

6.9 ± 1.6 b

a

N
)-J

TABLE 5.
EXPERIMENT II
ION CONCENTRATIONS AND Na+/K+ RATIOS IN THE BLOOD

Na+
(meq/1)

Treatment

*

K+
(meq/1)
*

c1(meq/l)
*

*

Intact Control

109.l ±

9.2

13.5 ± 3.5

58 "!: 8

8.2 ± 1.7

Intact Danazol

119.3 ±

7.6

21.3 "!: 4.7 a

66 ± 6

5,7±1.0a

Castrate Control

117.0 ± 13.1

18.3 ± 3.2 b

65 "!: • 6

6.6 ± 0.7

Castrate Danazol

113.4 ±

17.3 ± 4.7

67 ± 9

6.9 ± 3.2

9.5

*Meant Standard Deviation
(~ P .( . 02 compared to Intact Control)
( P <: • OS compared to Intact Control)

N
N

TABLE 6.
EXPERIMENT II
ION CONCENTRATIONS AND Na+/K+ RATIOS THE URINE

Treatment

Intact Control

c1-

Na+
(meq/1)

K+
(meq/ 1)

Cmeq/l)

*

*

*

124

±

49

174

±

45

117 ± 48

*

.73±.21

-------------------------------------------------------------------------------Intact Danazol

129 ± 56

177 ± 18

134 ± 46

. 71 ± .15

-- ---- ---- --- --------- ----- ------- ----- -- -- -- ----- -------------------- ------ ---Castrate Control

181 ± 44

196 ± 31

211 ± 71

.93 ± .21

- - - ------ ------ --- -- - - -- -- -------- - - ----- -- -- - -- -------- - - ----- - ----- ----- -- - --Castrate Danazol

195 ± 34

204 ±

8

*Mean+ Standard Deviation
ca P, : OS compared to Intact Control)

.96 ± .19

N

"'
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TABLE 7.
EXPERIMENT II
ZONA GLOMERULOSA THICKNESS

Treatment

*Thickness
(microns)

Intact Control

51.7

Intact Danazol

40.5 t 5.2 a

Castrate Control

33.0 t 7.2 b

Castrate Danazol

37.3 t 9.6a

±

5.1

*Mean~ Standard Deviation
ca

P £. 01 compared to Intact Control)

(b

P<:. 001 compared to Intact Control)
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DISCUSSION
In neither experiment were significant changes in
body weight observed, indicating no anabolic effect at
the doses administered.

It was mentioned previously

that anabolic effects were usually more prevalent at
higher doses according to Dmowski (1979).
Experiment I produced an unexpected increase in
adrenal weight due to castration alone (Table 1).
Ovariectomy has been shown by Kitay, et al. (1963) to
have an atrophic effect on the adrenal glands due to the
removal of the stimulatory effect of estrogens on the
release of ACTH from the pituitary.

Experiment II pro-

duced the expected decrease in adrenal weight.

The un-

expected result in Experiment I may be attributed to post
1

operative stress and the subsequent release of ACTH
which was still exhibiting a trophic effect on the day
the animals were sacrificed.

More polished surgical

technique along with the longer post operative period
before analysis accounts for the more expected observation
in Experiment II.
Nonsignificant ovarian weight reduction in Experiment I at all doses and a significant reduction in Experiment II may be attributed to one of three possible
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causes: 1) the antigonadotropic effect of Danazol by way
of inhibition on the pituitary-ovarian axis as indicated
by Dmowski (1979),

2) direct inhibition of steroidogen-

esis in the ovary as demonstrated by Barbieri,~ al.
(1977), or 3) a combination of the two.
The concentrations of sodium and potassium ions
are essential elements in electrolyte metabolism.

In the

kidney nephron sodium tends to be retained in the body
fluids while potassium tends to be eliminated into the
urine.

Chloride ion concentrations tend to correlate

with sodium ion concentrations as sodium ions are usually
retained in the blood or excreted in the urine as sodium
chloride.

Changes in the concentrations of these ions in

the blood and urine may indicate an effect on aldosterone,
either in terms of its synthesis, release, or mechanism
of action.
In Experiment I the most measurable effects of
Danazol were observed at a dosage of 4 mg/kg.

Significant

differences in ion concentrations and ratios were noted
between Danazol injected intact rats and intact controls,
while differences also occurred between castrate and
intact rats receiving this same dosage (Table 2 and 3).
The significant elevation of serum K+ and urine Na+ levels
.

+

and a decrease 1n the Na /K

+

ratio in the blood along with

a nonsignificant elevation in urine Cl- levels indicates
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that at a dosage of 4 mg/kg in intact rats, sodium chloride is being eliminated into the urine while K+ is being
retained in the blood to a greater extent than in control
rats.

These facts along with the significant reduction

in ovarian weight observed at this dosage led to the
selection of 4 mg/kg as the optimal dosage to be used in
Experiment II.
In Experiment II changes in electrolyte metabolism
in rat urine and serum (Tables 5 and 6) and the decrease
in the thickness of the zona glomerulosa (Table 7) in
intact Danazol treated rats suggests the inhibition of
aldosterone synthesis.

The electrolyte changes were

indicated by a decrease in the Na+/K+ ratio in the blood
as well as an elevation in blood K+ levels (Table 5).
If only electrolyte changes had been observed, influence
on the renin-angiotensin system might have been suspected,
The regression of the zona glomerulosa indicates that an
inhibition of synthesis rather than an inhibition of
the release of aldosterone is more probable.
Barbieri, et al. (1977) have shown that Danazol
inhibits three of the enzymes of steroidogenesis leading
from pregnenolone to the synthesis of corticosterone in
rat adrenal cells in vitro.

While data presented here

suggests the inhibition of aldosterone in vivo, it does
not indicate a mechanism of action.

It is not evident
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whether aldosterone synthesis is inhibited by Danazol's
inhibition of its precursor production or whether Danazol
directly inhibits the 18-hydroxylase activity.

This could

be explored in vitro by incubating rat adrenal cells with
Danazol and radioactive corticosterone as Barbieri, et~did in demonstrating the inhibition of the enzymes which
produced the precursors of aldosterone.

The data reveals

a greater inhibition on the, enzymes the closer you get to
the synthesis of aldosterone, that is, llS-hydroxylase is
inhibited more than 21-hydroxylase, which is inhibited
more than 3S-hydroxysteroid dehydrogenase (See Figure 2).
Watanuki, et al. (1978) have indicated the very distinct
possibility that the llS-hydroxylase and 18-hydroxylase
activities of the zona glomerulosa mitochondria are
actually catalyzed by only one enzyme instead of two.
If Danazol inhibits one of the enzyme's activities, there
is a good possibility that it inhibits the other as well.
To what extent this may occur is in need of further
research.
According to Dmowski (1979) work with radioactive
Danazol showing greater than plasma concentrations in the
adrenal glands indicates possibly a direct influence of
Danazol on the adrenal glands probably by means of binding to receptor sites.

Rifka, et al. (197 8) have reported

the existence of an adrenal cytosol androgen receptor
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which may mediate regression of the adrenals.

Since

Danazol is an androgen derivative, one possible explanation
for adrenal weight loss upon treatment with Danazol is the
binding of Danazol to this receptor.

No significant

differences were observed .between the castrate controls,
the castrated treated rats, or thi intact treated rats.
Ther•efore the effect observed between the intact treated
and the intact controls may be related to the decrease
in estrogens rather than a direct effect on the adrenal.
Estrogens are currently believed to regulate the expression of certain genes and, as a result, subsequent protein
formation (Turner and Bagnara, 1976).

The lack of

estrogens in castrated rats may cause a reduction of the
receptors for Danazol, possibly the adrenal androgen
receptor.

Further research with radioactive Danazol's

ability to bind to this androgen receptor and the
determination of whether or not castration does, in effect,
reduce the synthesis of these receptors would clarify this
issue.
It should be noted that the length of time of
administration affected the observed action of Danazol on
electrolyte metabolism.

In the ten day experiment at a

dosage of 4 mg/kg, castrates exhibited significantly
higher serum Na+ and lower serum K+ levels than intact
rats receiving the same dosage (Table 2).

Levels in
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Experiment II, however, were not significantly different.
The difference in Experiment I may be attributed to the
post operative increase in aldosterone immediately following surgery due to fluid loss.

The longer post operative

period and reduction of post operative stress eliminated
this effect in Experiment II as no differences in electrolyte concentrations or ratios were observed between intact
or castrate treated rats (Tables 5 and 6).
Although research has shown Danazol's ability to
inhibit steroidogenesis in vitro, this thesis presents
data which suggests the inhibition of aldosterone synthesis by Danazol in vivo in rats.

However, more research

is needed on the in vivo inhibition of steroidogenesis by
Danazol, particularly in humans.

Wentz,~ al. (1975)

studied adrenal response in.humans at a dosage of 800
mg/day which is the normal dosage recommended for treatment of endometriosis.

They used a synthetic ACTH com-

pound, cosyntropin, to test adrenal response as well as
a metyrapone challenge which inhibits llS-hydroxylation.
These. tests were run following chronic Danazol administration and showed normal cortisol elevation in the bloodstream compar~d to controls when injected with cosyntropin, and normal ACTH rise following the metyrapone
challenge.

At this dosage in humans, there appears to be

no evidence of inhibition upon cortisol synthesis.
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Because aldosterone is produced by a different pathway,
evidence in this thesis indicates a need for research in
the area of Danazol's effect on the human pathway leading
to the synthesis of aldosterone.

This research would be

especially important in patients treated -with Danazol
who may engage in strenuous activities since they may have
a tendency to lose large amounts of salt and water from
their body during activity.
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